CA2397861C - Vaccination contre l'herpesvirose canine et vaccins a cet egard - Google Patents

Vaccination contre l'herpesvirose canine et vaccins a cet egard Download PDF

Info

Publication number
CA2397861C
CA2397861C CA2397861A CA2397861A CA2397861C CA 2397861 C CA2397861 C CA 2397861C CA 2397861 A CA2397861 A CA 2397861A CA 2397861 A CA2397861 A CA 2397861A CA 2397861 C CA2397861 C CA 2397861C
Authority
CA
Canada
Prior art keywords
chv
use according
detergent
vaccine
inactivated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2397861A
Other languages
English (en)
Other versions
CA2397861A1 (fr
Inventor
Herve Poulet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health France SAS
Original Assignee
Merial SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial SAS filed Critical Merial SAS
Publication of CA2397861A1 publication Critical patent/CA2397861A1/fr
Application granted granted Critical
Publication of CA2397861C publication Critical patent/CA2397861C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Utilisation d'antigène de CHV pour la préparation d'un vaccin contre l'herpèsvirose canine, destiné à être administré chez la chienne gestante le plus près possible de la mise bas, de préférence pendant le dernier tiers de la gestation, et produisant un taux d'anticorps anti-CHV élevé chez la chienne gestante au moment de la mise bas, induisant une protection chez les chiots par transfert d'anticorps lors de l'allaitement. Vaccin anti-CHV inactivé ou de sous-unités, utilisable pour la vaccination des femelles gestantes pour protéger les chiots par tranfert d'anticorps.
CA2397861A 2000-01-21 2001-01-19 Vaccination contre l'herpesvirose canine et vaccins a cet egard Expired - Lifetime CA2397861C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0000797A FR2804026B1 (fr) 2000-01-21 2000-01-21 Vaccination contre l'herpesvirose canine et vaccins
FR00/00797 2000-01-21
PCT/FR2001/000189 WO2001052887A2 (fr) 2000-01-21 2001-01-19 Vaccination contre l"herpesvirose canine et vaccins

Publications (2)

Publication Number Publication Date
CA2397861A1 CA2397861A1 (fr) 2001-07-26
CA2397861C true CA2397861C (fr) 2017-04-04

Family

ID=8846182

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2397861A Expired - Lifetime CA2397861C (fr) 2000-01-21 2001-01-19 Vaccination contre l'herpesvirose canine et vaccins a cet egard

Country Status (13)

Country Link
EP (1) EP1248648B1 (fr)
JP (1) JP2003520249A (fr)
AT (1) ATE540693T1 (fr)
AU (1) AU782657C (fr)
BR (2) BR0107771A (fr)
CA (1) CA2397861C (fr)
FR (1) FR2804026B1 (fr)
HU (1) HU228703B1 (fr)
MX (1) MXPA02007115A (fr)
NZ (1) NZ520242A (fr)
PL (1) PL209070B1 (fr)
WO (1) WO2001052887A2 (fr)
ZA (1) ZA200205830B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056390A1 (fr) * 2002-12-19 2004-07-08 Akzo Nobel Patent Department Vaccin trivalent a transfert d'anticorps maternels par l'intermediaire du lait
CA2596920C (fr) * 2005-01-28 2015-05-05 North-West University Combinaison de lipides et d'oxyde nitreux comme adjuvant permettant d'ameliorer l'efficacite de vaccins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
AU532186B2 (en) 1978-07-21 1983-09-22 Merck & Co., Inc. Herpes virus vaccine
IE63692B1 (en) * 1987-11-03 1995-05-31 Syntex Inc Vaccine adjuvant
US5753235A (en) * 1996-02-15 1998-05-19 Heska Corporation Recombinant canine herpesviruses
JPH11106351A (ja) * 1997-10-02 1999-04-20 Chemo Sero Therapeut Res Inst オイルアジュバントワクチンおよびその製造方法
US6093564A (en) * 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
GB9726555D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) * 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves

Also Published As

Publication number Publication date
BRPI0107771B1 (pt) 2017-06-13
CA2397861A1 (fr) 2001-07-26
WO2001052887A2 (fr) 2001-07-26
AU782657C (en) 2006-07-13
FR2804026B1 (fr) 2004-06-11
FR2804026A1 (fr) 2001-07-27
AU3383101A (en) 2001-07-31
ATE540693T1 (de) 2012-01-15
ZA200205830B (en) 2003-09-29
PL356556A1 (en) 2004-06-28
PL209070B1 (pl) 2011-07-29
HUP0203831A3 (en) 2004-07-28
JP2003520249A (ja) 2003-07-02
WO2001052887A3 (fr) 2002-01-31
MXPA02007115A (es) 2003-01-28
NZ520242A (en) 2004-06-25
EP1248648B1 (fr) 2012-01-11
EP1248648A2 (fr) 2002-10-16
HUP0203831A2 (hu) 2003-03-28
BR0107771A (pt) 2002-11-12
AU782657B2 (en) 2005-08-18
HU228703B1 (en) 2013-05-28

Similar Documents

Publication Publication Date Title
TWI733653B (zh) Ｆｍｄｖ重組疫苗及其用途
JP3993230B2 (ja) 改良された修飾ｂｒｓｖ生ワクチン
JP4718778B2 (ja) ウエストナイルワクチン
JP6876127B2 (ja) ブタパルボウイルスに対するワクチン
CN107250353B (zh) 二价猪流感病毒疫苗
AU2019204526A1 (en) Inactivated canine influenza vaccines and methods of making and uses thereof
JP4873632B2 (ja) 改良された不活化ｆｃｖワクチン
JP2008528504A (ja) ネコカリシウイルスに対する改良ワクチン
CN111956798B (zh) 用于猪伪狂犬灭活疫苗的复合免疫增强剂及其应用
US9913896B2 (en) Attenuated parvovirus vaccine for muscovy duck parvovirus and goose parvovirus (derzsy's disease)
US6551598B2 (en) Vaccination against canine herpesvirosis and vaccines therefor
CA2397861C (fr) Vaccination contre l'herpesvirose canine et vaccins a cet egard
Rehmani et al. The influence of adjuvants on oral vaccination of chickens against Newcastle disease
CN116390753A (zh) 犬细小病毒
Kamaraj et al. Serological response in cattle immunized with inactivated oil and Algel adjuvant vaccines against infectious bovine rhinotracheitis.
KR100934687B1 (ko) 고양이 칼리시바이러스 질병에 대한 불활성화 백신
RU2812330C1 (ru) Ассоциированная вакцина против панлейкопении, калицивироза и вирусного ринотрахеита кошек
TW201125579A (en) Heterologous prime-boost immunization regimen
US20240226270A1 (en) Novel Vaccine Compositions for Porcine Epidemic Diarrhea Virus and Porcine Deltacoronavirus
RU2395299C1 (ru) Вакцина инактивированная комбинированная против инфекционного ринотрахеита, вирусной диареи, рота-, коронавирусной болезней и лептоспироза крупного рогатого скота

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20210119